Calidi Biotherapeutics, Inc. (CLDI) 10-Year Financial Performance & Capital Metrics

CLDI • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutCalidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is based in San Diego, California.Show more

Revenue $0
EBITDA -$20M +27.0%
Net Income -$22M +24.2%
EPS (Diluted) -35.70 +82.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -1125.15%
ROIC -
Debt/Equity 3.58
Interest Coverage -23.34 -201.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.4x book value

✗Weaknesses

✗High debt to equity ratio of 3.6x
✗Weak momentum: RS Rating 5 (bottom 5%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM24.08%

EPS CAGR

10Y-

5Y-

3Y-

TTM87.46%

ROCE

10Y Avg-973.66%

5Y Avg-973.66%

3Y Avg-973.66%

Latest-973.66%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	449K	45K	0	0
Revenue Growth %	-	-	-0.9%	-1%	-
Cost of Goods Sold+	0	94K	274K	1.26M	0
COGS % of Revenue	-	0.21%	6.09%	-	-
Gross Profit+	0	355K	-229K	-1.26M	0
Gross Margin %	-	0.79%	-5.09%	-	-
Gross Profit Growth %	-	-	-1.65%	-4.48%	1%
Operating Expenses+	6.77M	10.84M	22.9M	27.74M	21.78M
OpEx % of Revenue	-	24.14%	508.87%	-	-
Selling, General & Admin	3.59M	6.16M	15.64M	15.98M	12.9M
SG&A % of Revenue	-	13.73%	347.6%	-	-
Research & Development	3.18M	4.67M	7.26M	13.01M	8.88M
R&D % of Revenue	-	10.41%	161.27%	-	-
Other Operating Expenses	0	0	0	-1.26M	0
Operating Income+	-6.77M	-10.48M	-23.13M	-28.99M	-21.78M
Operating Margin %	-	-23.35%	-513.96%	-	-
Operating Income Growth %	-	-0.55%	-1.21%	-0.25%	0.25%
EBITDA+	-6.67M	-10.33M	-22.87M	-27.74M	-20.24M
EBITDA Margin %	-	-23%	-508.18%	-	-
EBITDA Growth %	-	-0.55%	-1.21%	-0.21%	0.27%
D&A (Non-Cash Add-back)	107K	156K	260K	1.26M	1.53M
EBIT	-6.77M	-9.61M	-25.26M	-25.45M	-21.26M
Net Interest Income+	-163K	-614K	-158K	-3.75M	-933K
Interest Income	0	0	0	0	0
Interest Expense	163K	614K	158K	3.75M	933K
Other Income/Expense	-1.16M	13.88M	-2.29M	-208K	-419K
Pretax Income+	-7.93M	3.4M	-25.42M	-29.2M	-22.2M
Pretax Margin %	-	7.57%	-564.8%	-	-
Income Tax+	4K	11K	11K	16K	14K
Effective Tax Rate %	1%	-3.22%	1%	1%	1%
Net Income+	-7.94M	-10.93M	-25.43M	-29.22M	-22.14M
Net Margin %	-	-24.35%	-565.04%	-	-
Net Income Growth %	-	-0.38%	-1.33%	-0.15%	0.24%
Net Income (Continuing)	-7.94M	3.39M	-25.43M	-29.22M	-22.21M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	434K
EPS (Diluted)+	-2.64	14.16	-358.80	-207.61	-35.70
EPS Growth %	-	6.36%	-26.34%	0.42%	0.83%
EPS (Basic)	-2.64	14.16	-358.80	-207.61	-35.70
Diluted Shares Outstanding	2.98M	238.63K	70.59K	140.16K	664.41K
Basic Shares Outstanding	2.98M	238.63K	70.59K	140.16K	664.41K
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	513K	2.74M	786K	4.3M	10.23M
Cash & Short-Term Investments	420K	2.14M	372K	2.05M	9.59M
Cash Only	420K	2.14M	372K	2.05M	9.59M
Short-Term Investments	0	0	0	0	0
Accounts Receivable	0	0	0	1.36M	0
Days Sales Outstanding	-	-	-	-	-
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	93K	100K	303K	125K	249K
Total Non-Current Assets+	1.34M	651K	1.81M	5.72M	3.96M
Property, Plant & Equipment	723K	585K	1.09M	5.34M	2.93M
Fixed Asset Turnover	-	0.77x	0.04x	-	-
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	0
Long-Term Investments	0	0	0	230K	129K
Other Non-Current Assets	616K	66K	725K	143K	892K
Total Assets+	1.85M	3.39M	2.6M	10.02M	14.18M
Asset Turnover	-	0.13x	0.02x	-	-
Asset Growth %	-	0.83%	-0.23%	2.86%	0.42%
Total Current Liabilities+	8.89M	25.96M	42.99M	10.23M	9.5M
Accounts Payable	822K	624K	2.12M	2.88M	2.07M
Days Payables Outstanding	-	2.42K	2.83K	836.07	-
Short-Term Debt	4.94M	5M	5.42M	807K	3.18M
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	1.1M	16.69M	29.83M	0	2K
Current Ratio	0.06x	0.11x	0.02x	0.42x	1.08x
Quick Ratio	0.06x	0.11x	0.02x	0.42x	1.08x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	15.44M	43K	10.05M	8.02M	2.72M
Long-Term Debt	6.37M	0	0	2.06M	600K
Capital Lease Obligations	72K	43K	447K	3.25M	1.99M
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	9M	0	9.6M	2.71M	128K
Total Liabilities	24.33M	26M	53.04M	18.25M	12.21M
Total Debt+	11.72M	5.18M	5.99M	7.24M	7.04M
Net Debt	11.3M	3.04M	5.62M	5.19M	-2.56M
Debt / Equity	-	-	-	-	3.58x
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-41.55x	-17.07x	-146.38x	-7.73x	-23.34x
Total Equity+	-22.48M	-22.61M	-50.44M	-8.23M	1.97M
Equity Growth %	-	-0.01%	-1.23%	0.84%	1.24%
Book Value per Share	-7.54	-94.76	-714.54	-58.75	2.96
Total Shareholders' Equity	-22.48M	-22.61M	-50.44M	-8.23M	1.53M
Common Stock	2K	2K	2K	4K	2K
Retained Earnings	-34.44M	-44.93M	-70.36M	-99.57M	-121.72M
Treasury Stock	0	0	0	0	0
Accumulated OCI	6K	-1K	-14K	-47K	-28K
Minority Interest	0	0	0	0	434K

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.83M	-7.77M	-13.21M	-26.98M	-19.69M
Operating CF Margin %	-	-17.31%	-293.64%	-	-
Operating CF Growth %	-	-0.61%	-0.7%	-1.04%	0.27%
Net Income	-7.94M	-10.93M	-25.43M	-29.22M	-22.21M
Depreciation & Amortization	184K	153K	260K	1.26M	1.53M
Stock-Based Compensation	968K	1.33M	0	4.81M	2.96M
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	1.01M	582K	8.38M	2.41M	-279K
Working Capital Changes	945K	1.1M	3.57M	-6.24M	-1.7M
Change in Receivables	0	0	-870	0	0
Change in Inventory	0	0	0	0	0
Change in Payables	293K	-239K	1.62M	-6.17M	-628K
Cash from Investing+	-388K	-215K	-494K	-478K	-16K
Capital Expenditures	-351K	-206K	-428K	-585K	0
CapEx % of Revenue	-	0.46%	9.51%	-	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	-37K	-9K	-190.08M	98K	-16K
Cash from Financing+	4.7M	9.81M	12.09M	29.04M	27.36M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	-1.67M
Share Repurchases	-	-	-	-	-
Other Financing	-4K	8.03M	-58K	885K	9.05M
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-5.18M	-7.98M	-13.64M	-27.57M	-19.71M
FCF Margin %	-	-17.77%	-303.16%	-	-
FCF Growth %	-	-0.54%	-0.71%	-1.02%	0.29%
FCF per Share	-1.74	-33.44	-193.25	-196.69	-29.67
FCF Conversion (FCF/Net Income)	0.61x	0.71x	0.52x	0.92x	0.89x
Interest Paid	20K	45K	0	404K	140K
Taxes Paid	2K	8K	0	11K	14K

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-	-1125.15%
Gross Margin	-	79.06%	-508.89%	-	-
Net Margin	-	-2434.97%	-56504.44%	-	-
Debt / Equity	-	-	-	-	3.58x
Interest Coverage	-41.55x	-17.07x	-146.38x	-7.73x	-23.34x
FCF Conversion	0.61x	0.71x	0.52x	0.92x	0.89x
Revenue Growth	-	-	-89.98%	-100%	-

Frequently Asked Questions

Growth & Financials

Calidi Biotherapeutics, Inc. (CLDI) grew revenue by 0.0% over the past year. Growth has been modest.

Calidi Biotherapeutics, Inc. (CLDI) reported a net loss of $19.9M for fiscal year 2024.

Dividend & Returns

Yes, Calidi Biotherapeutics, Inc. (CLDI) pays a dividend with a yield of 100.00%. This makes it attractive for income-focused investors.

Calidi Biotherapeutics, Inc. (CLDI) has a return on equity (ROE) of -1125.2%. Negative ROE indicates the company is unprofitable.

Calidi Biotherapeutics, Inc. (CLDI) had negative free cash flow of $21.8M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener